dihexa subcutaneous dosage clinical trials status human trial Dihexa shows neurotrophic activity exceeding BDNF in preclinical studies DIHEXA FDA Panel Backs Peptide BPC-157

When it accepts electrons (is reduced), it becomes colorless (Leukomethylene Blue)

Refrigeration (2C8C) significantly slows down any potential bacterial activity and helps maintain the efficacy of the benzyl alcohol preservative within the 28-day window

These injections contain a mixture of vitamins and amino acids believed to boost metabolism and aid in fat burning

There's no prescription drug containing BPC-157 that's legally approved for human use in treating injuries, inflammation, gut issues, or pain

Verify current regulatory status, as it continues to evolve

Authentication limits and sourcing context: Pfizer's identification article, Pfizer counterfeiting guidance, and Health Canada counterfeit guidance